Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Age 18 - 75 years~* Anti-GAD antibodies negative (Glutamic Acid Decarboxylase)~* C-peptide levels ≥ 1.5 ng/mL~* Fasting blood glucose \> 126 mg/dl~* HbA1c 8.0 - 10.5 %~* BMI 25.0 - 45.0 kg/m2~* Previous therapy with BBIT (basal insulin and at least once daily bolus insulin)~Exclusion Criteria:~* Use of any oral antidiabetic treatment except for metformin (i.e., sulphonylureas, DPP-IV inhibitors, thiazolidinediones, SGLT-2 inhibitors (Sodium dependent glucose transporter) or GLP-1 analogues (glucagone like peptide) within the last three months prior to Screening~* Repeated episodes of severe hypoglycaemia within the last six months prior to Screening~* History of diabetic ketoacidosis, precoma diabetica, or diabetic coma~* Treatment with any other investigational drug within the last three months before Screening~* Acute infections within the last four weeks prior to Screening~* Recurrent urogenital infections~* History of pancreatitis~* Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures~* History of severe or multiple allergies~* Concomitant participation in other clinical trials~* Type 1 diabetes~* Cardiovascular disease Clinically relevant ventricular tachycardia or ventricular fibrillation, 3rd degree AV block or Torsades de Pointes or treatment with antiarrhythmic drugs. Percutaneous coronary intervention within the past 6 months. Any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery; unstable angina; or stroke.~Uncontrolled unstable angina pectoris or history of pericarditis, myocarditis, endocarditis. Congestive heart failure NYHA (New York Heart Association) class III or IV. Increased risk of thromboembolism, e.g. subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator.~* Malignancy including leukemia and lymphoma within the last 5y.~* Liver disease such as cirrhosis or chronic active hepatitis.~* Significant renal dysfunction (see also exclusion criteria laboratory abnormalities).~* State after kidney transplantation~* Endocrine disease:~Acromegaly or treatment with growth hormone or similar drugs. Chronic oral or parenteral corticosteroid treatment (\>7 consecutive days of treatment) within 8 weeks; thyroid hormone replacement is allowed if the dosage has been stable for at least 3 months and the TSH is within normal limits~•Any of the following significant laboratory abnormalities: eGFR (as calculated by the MDRD equation) \< 60 ml/min at Screening Fasting triglycerides \>700 mg/dl (\>7.9 mmol/l)~* Systolic blood pressure outside the range of 100-160 mmHg or diastolic blood pressure above 95 mmHg at Screening~* History of active substance abuse (including alcohol \> 40g/day) within the past 2 years.~* Pregnancy or childbearing potential without adequate contraception~* Present therapy with systemic steroids~* Presence of psychiatric disorder or intake of anti-depressive or anti-psychotic agents with the exception of benzodiazepines and SSRIs/SNRI´s (selective serotonin reuptake inhibitor)~* Potentially unreliable subjects, and those judged by the investigator to be unsuitable for the study.~* Contraindications for Magnetic resonance (MR) scanning such as persons with cardiac pacemaker and implants out of metal or claustrophobia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Verum (Type: ACTIVE_COMPARATOR): Dapagliflozin 10 mg + Saxagliptin 5 mg, each once daily, for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1 10 mg + Placebo 2 5 mg, each once daily, for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).